Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein.

Tang A, Chen Z, Cox KS, Su HP, Callahan C, Fridman A, Zhang L, Patel SB, Cejas PJ, Swoyer R, Touch S, Citron MP, Govindarajan D, Luo B, Eddins M, Reid JC, Soisson SM, Galli J, Wang D, Wen Z, Heidecker GJ, Casimiro DR, DiStefano DJ, Vora KA.

Nat Commun. 2019 Sep 12;10(1):4153. doi: 10.1038/s41467-019-12137-1.

2.

A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.

Wang D, Phan S, DiStefano DJ, Citron MP, Callahan CL, Indrawati L, Dubey SA, Heidecker GJ, Govindarajan D, Liang X, He B, Espeseth AS.

J Virol. 2017 May 12;91(11). pii: e00066-17. doi: 10.1128/JVI.00066-17. Print 2017 Jun 1.

3.

Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection.

Mallajosyula VV, Citron M, Ferrara F, Lu X, Callahan C, Heidecker GJ, Sarma SP, Flynn JA, Temperton NJ, Liang X, Varadarajan R.

Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):E2514-23. doi: 10.1073/pnas.1402766111. Epub 2014 Jun 9.

4.

Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge.

Bommakanti G, Lu X, Citron MP, Najar TA, Heidecker GJ, ter Meulen J, Varadarajan R, Liang X.

J Virol. 2012 Dec;86(24):13434-44. doi: 10.1128/JVI.01429-12. Epub 2012 Sep 26.

5.

Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge.

Bommakanti G, Citron MP, Hepler RW, Callahan C, Heidecker GJ, Najar TA, Lu X, Joyce JG, Shiver JW, Casimiro DR, ter Meulen J, Liang X, Varadarajan R.

Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13701-6. doi: 10.1073/pnas.1007465107. Epub 2010 Jul 6.

6.

Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge.

Casimiro DR, Cox K, Tang A, Sykes KJ, Feng M, Wang F, Bett A, Schleif WA, Liang X, Flynn J, Tobery TW, Wilson K, Finnefrock A, Huang L, Vitelli S, Lin J, Patel D, Davies ME, Heidecker GJ, Freed DC, Dubey S, O'Connor DH, Watkins DI, Zhang ZQ, Shiver JW.

J Virol. 2010 Mar;84(6):2996-3003. doi: 10.1128/JVI.00969-09. Epub 2009 Dec 30.

7.

Robust, vaccine-induced CD8(+) T lymphocyte response against an out-of-frame epitope.

Maness NJ, Wilson NA, Reed JS, Piaskowski SM, Sacha JB, Walsh AD, Thoryk E, Heidecker GJ, Citron MP, Liang X, Bett AJ, Casimiro DR, Watkins DI.

J Immunol. 2010 Jan 1;184(1):67-72. doi: 10.4049/jimmunol.0903118. Epub 2009 Nov 30.

8.

Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge.

Wilson NA, Keele BF, Reed JS, Piaskowski SM, MacNair CE, Bett AJ, Liang X, Wang F, Thoryk E, Heidecker GJ, Citron MP, Huang L, Lin J, Vitelli S, Ahn CD, Kaizu M, Maness NJ, Reynolds MR, Friedrich TC, Loffredo JT, Rakasz EG, Erickson S, Allison DB, Piatak M Jr, Lifson JD, Shiver JW, Casimiro DR, Shaw GM, Hahn BH, Watkins DI.

J Virol. 2009 Jul;83(13):6508-21. doi: 10.1128/JVI.00272-09. Epub 2009 Apr 29.

9.

Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons.

Shughrue PJ, Acton PJ, Breese RS, Zhao WQ, Chen-Dodson E, Hepler RW, Wolfe AL, Matthews M, Heidecker GJ, Joyce JG, Villarreal SA, Kinney GG.

Neurobiol Aging. 2010 Feb;31(2):189-202. doi: 10.1016/j.neurobiolaging.2008.04.003.

PMID:
18486276
10.

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag.

Casimiro DR, Wang F, Schleif WA, Liang X, Zhang ZQ, Tobery TW, Davies ME, McDermott AB, O'Connor DH, Fridman A, Bagchi A, Tussey LG, Bett AJ, Finnefrock AC, Fu TM, Tang A, Wilson KA, Chen M, Perry HC, Heidecker GJ, Freed DC, Carella A, Punt KS, Sykes KJ, Huang L, Ausensi VI, Bachinsky M, Sadasivan-Nair U, Watkins DI, Emini EA, Shiver JW.

J Virol. 2005 Dec;79(24):15547-55.

11.

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.

Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon Y, Shi L, Chastain MA, Condra JH, Davies ME, Liao J, Emini EA, Shiver JW.

Vaccine. 2004 Aug 13;22(23-24):2993-3003.

PMID:
15297047
12.

Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.

Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, Dubey S, Zhu DM, Nawrocki D, Mach H, Troutman R, Isopi L, Williams D, Hurni W, Xu Z, Smith JG, Wang S, Liu X, Guan L, Long R, Trigona W, Heidecker GJ, Perry HC, Persaud N, Toner TJ, Su Q, Liang X, Youil R, Chastain M, Bett AJ, Volkin DB, Emini EA, Shiver JW.

J Virol. 2003 Jun;77(11):6305-13.

13.

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA.

Nature. 2002 Jan 17;415(6869):331-5.

PMID:
11797011
14.

Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene.

Casimiro DR, Tang A, Perry HC, Long RS, Chen M, Heidecker GJ, Davies ME, Freed DC, Persaud NV, Dubey S, Smith JG, Havlir D, Richman D, Chastain MA, Simon AJ, Fu TM, Emini EA, Shiver JW.

J Virol. 2002 Jan;76(1):185-94.

15.

An enhanced and scalable process for the purification of SIV Gag-specific MHC tetramer.

Grimm KM, Trigona WL, Heidecker GJ, Joyce JG, Fu TM, Shiver JW, Keller PM, Cook JC.

Protein Expr Purif. 2001 Nov;23(2):270-81.

PMID:
11676602
16.

Nontypeable Haemophilus influenzae susceptibility: effect of inoculum size and beta-lactamase production.

Gould JM, Heidecker GJ, LiPuma JJ.

Diagn Microbiol Infect Dis. 1996 Oct;26(2):95-8.

PMID:
8985663
17.

Survival of Burkholderia cepacia on environmental surfaces.

Drabick JA, Gracely EJ, Heidecker GJ, LiPuma JJ.

J Hosp Infect. 1996 Apr;32(4):267-76.

PMID:
8744511
18.

Detection of Pseudomonas (Burkholderia) cepacia using PCR.

Campbell PW 3rd, Phillips JA 3rd, Heidecker GJ, Krishnamani MR, Zahorchak R, Stull TL.

Pediatr Pulmonol. 1995 Jul;20(1):44-9.

PMID:
7478781
19.

Construction of an ori cassette for adapting shuttle vectors for use in Haemophilus influenzae.

Heidecker GJ, Pozsgay JM, Stull TL.

Gene. 1994 Dec 2;150(1):141-4.

PMID:
7959040

Supplemental Content

Loading ...
Support Center